|
FDA backs Astellas’ Astragraf XL for kidney transplant rejection prophylaxis
The Pharma Letter … Astellas Pharma’s (TYO: 4503) Astragraf XL (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab … |
Astellas Pharma secures US FDA approval for ASTAGRAF XLPharmaceutical Business Review… for the prophylaxis of kidney transplant rejection in adult recipients. The prescription medicine used with other medicines is indicated for kidney transplant pati…
|
Astellas reports FDA approval of anti-rejection drug
NephrologyNews.com The drug is used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. “Each transplant recipient is different and requires a personalized treatment approach,” said Sef Kurstjens, MD, PhD., chief medical officer … |
|
Astellas Announces FDA Approval of ASTAGRAF XL™ (tacrolimus extended …
Yahoo! News … Administration (FDA) has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without … |
生物谷 |
安斯泰来他克莫司缓释胶囊（ASTAGRAF XL）获FDA批准
生物谷 2013年7月20日讯/生物谷BIOON/ –安斯泰来（Astellas）美国子公司今天宣布，ASTAGRAF XL（他克莫司缓释胶囊，tacrolimus extended release capsules）获FDA批准，与霉酚酸酯（MMF）及皮质类醇联用、结合或无巴利昔单抗 … |
Astellas Announces FDA Approval of ASTAGRAF XL(TM) (tacrolimus extended …MarketWatchThe two primary, randomized, comparative phase 3 clinical studies to support FDA approval enrolled 1,093 patients (545 on tacrolimus extended-release) in the U.S., Eu…
Astellas Announces FDA Approval of ASTAGRAF XL(TM) (tacrolimus extended …Wall Street Journal… Administration (FDA) has approved ASTAGRAF XL(TM) (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a ki…
|
FDA approves Astellas’ ASTAGRAF XL for prophylaxis of organ rejection in …
News-Medical.net … Administration (FDA) has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without … |
|
Astellas Announces FDA Approval of ASTAGRAF XL™ (tacrolimus extended …
The Herald | HeraldOnline.com … Administration (FDA) has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without … |
Efficacy and safety of concentration-controlled everolimus with reduced-dose …7thSpace Interactive (press release)All patients received basiliximab and corticosteroids. Key endpoints at month 12 were composite efficacy failure (treated biopsy-proven …